AnGes, Inc.
Built from real-time financials and updated daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a AMGXF research report →
Companywww.anges.co.jp
AnGes, Inc. , a biopharmaceutical company, engages in the research and development of gene-based medical products. Its lead product is Hepatocyte Growth Factor (HGF) Plasmid, a gene therapy for the treatment of critical limb ischemia, a serious impairment of blood circulation in the leg.
- CEO
- Ei Yamada
- IPO
- 2017
- Employees
- 55
- HQ
- Ibaraki, JP
Price Chart
Valuation
- Market Cap
- $142.50M
- P/E
- -3.91
- P/S
- 21.33
- P/B
- 9.57
- EV/EBITDA
- -3.00
- Div Yield
- 0.00%
Profitability
- Gross Margin
- 38.14%
- Op Margin
- -592.80%
- Net Margin
- -545.66%
- ROE
- -156.47%
- ROIC
- -186.57%
Growth & Income
- Revenue
- $874.88M · 35.93%
- Net Income
- $-5,127,739,549 · 81.77%
- EPS
- $-14.45 · 88.58%
- Op Income
- $-5,149,882,816
- FCF YoY
- 13.77%
Performance & Tape
- 52W High
- $0.36
- 52W Low
- $0.34
- 50D MA
- $0.36
- 200D MA
- $0.36
- Beta
- 0.66
- Avg Volume
- 504.64
Get TickerSpark's AI analysis on AMGXF
Pro members can request AI-generated analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →30-day money-back guarantee · cancel anytime
Our AMGXF Coverage
We haven't published any research on AMGXF yet
For a full analyst-grade research report — grades, price targets, full financials, chart analysis — generate one on demand.
Generate AMGXF Report →